Tag: Stem Cells
Autologous Hematopoietic Stem Cell Transplant Slows Disability Progression in MS
Slowing of disability progression and higher likelihood of disability improvement observed compared with standard disease-modifying therapies
Bridge Therapy Between Induction, ASCT May Slow Neuroblastoma
Three-year event-free survival significantly improved for patients with end-induction stable metastatic disease receiving bridge therapy
AACR: Resistance Mechanisms to CAR-T Cell Therapy ID’d in ALL
Mechanisms of resistance detectable prior to treatment and include hypermethylation of PCR2 targets in embryonic and cancer stem cells
AAD: Skin Videomicroscopy Biomarker May Help Predict Cancer Relapse
Assessment of leukocytes adherent to and rolling along vessel wall may help predict outcomes after HCT for hematologic cancer
Frailty Mars Outcomes After aHSCT in Lymphoid Malignancies
Links found for frailty with in-hospital mortality, prolonged length of stay for patients with NHL, HL, MM undergoing aHSCT
Survival Increase Seen for Adults With Relapsed Ph+ ALL
From 2000 to 2019, overall survival progressively improved for patients with Philadelphia-positive ALL who had posttransplant relapse
FDA Approves Livtencity for Posttransplant Cytomegalovirus
Livtencity is indicated for posttransplant CMV that does not respond to available antiviral treatments
ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease
The use of HSCT for sickle cell disease is evolving, and no randomized controlled trials were identified in the evidence review for this guideline
Ruxolitinib Best for Glucocorticoid-Refractory, -Dependent GVHD
Overall response, failure-free survival, symptom response significantly greater with ruxolitinib versus control therapy
Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma
Three- and five-year overall survival similar with allogeneic or autologous HSCT, but transplant-related mortality higher with allogeneic HSCT
